The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study

Chad A. Hamilton,Austin Miller,Caela Miller,Thomas C. Krivak,John H. Farley,Mildred R. Chernofsky,Michael P. Stany,G. Scott Rose,Maurie Markman,Robert F. Ozols,Deborah K. Armstrong,G. Larry Maxwell

The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study

2011

Chad A. Hamilton
Austin Miller
Caela Miller
Thomas C. Krivak
John H. Farley
Mildred R. Chernofsky
Michael P. Stany
G. Scott Rose
Maurie Markman
Robert F. Ozols
Deborah K. Armstrong
G. Larry Maxwell

Objective To assess the survival impact of initial disease distribution on patients with stage III epithelial ovarian cancer (EOC) cytoreduced to microscopic residual.

Keywords:

Carboplatin
Gynecologic oncology
Proportional hazards model
Ovarian cancer
Gynecology
Cisplatin
Survival rate
Paclitaxel
Disease
Oncology
Internal medicine
Medicine
disease distribution
epithelial ovarian cancer
in patient
group study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations